These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
620 related articles for article (PubMed ID: 32079034)
21. Comparative short-term efficacy and safety of add-on anti-seizure medications in Dravet syndrome: An indirect treatment comparison. Devi N; Madaan P; Asrar MM; Sahu JK; Bansal D Seizure; 2021 Oct; 91():316-324. PubMed ID: 34274891 [TBL] [Abstract][Full Text] [Related]
22. From genotype to phenotype in Dravet disease. Gataullina S; Dulac O Seizure; 2017 Jan; 44():58-64. PubMed ID: 27817982 [TBL] [Abstract][Full Text] [Related]
23. The contribution of fenfluramine to the treatment of Dravet syndrome in Spain through Multi-Criteria Decision Analysis. Gil-Nagel A; Falip M; Sánchez-Carpintero R; Abad-Sazatornil MR; Poveda JL; Aibar JÁ; Cardenal-Muñoz E; Aras LM; Sánchez R; Sancho-López A; Trillo-Mata JL; Torrejón M; Gil A Epilepsy Behav; 2022 Jul; 132():108711. PubMed ID: 35588562 [TBL] [Abstract][Full Text] [Related]
25. The European patient with Dravet syndrome: results from a parent-reported survey on antiepileptic drug use in the European population with Dravet syndrome. Aras LM; Isla J; Mingorance-Le Meur A Epilepsy Behav; 2015 Mar; 44():104-9. PubMed ID: 25666511 [TBL] [Abstract][Full Text] [Related]
26. Advancements in Dravet Syndrome Therapeutics: A Comprehensive Look at Present and Future Treatment Horizons: A Focused Review. Mahesan A; Kamila G; Gulati S Ann Indian Acad Neurol; 2024 Jul; 27(4):352-357. PubMed ID: 39196806 [TBL] [Abstract][Full Text] [Related]
27. Marked efficacy of combined three-drug therapy (Sodium Valproate, Topiramate and Stiripentol) in a patient with Dravet syndrome. Morimoto M; Shimakawa S; Hashimoto T; Kitaoka T; Kyotani S J Clin Pharm Ther; 2018 Aug; 43(4):571-573. PubMed ID: 29265387 [TBL] [Abstract][Full Text] [Related]
28. Patients with dravet syndrome in the era of stiripentol: A French cohort cross-sectional study. De Liso P; Chemaly N; Laschet J; Barnerias C; Hully M; Leunen D; Desguerre I; Chiron C; Dulac O; Nabbout R Epilepsy Res; 2016 Sep; 125():42-6. PubMed ID: 27389706 [TBL] [Abstract][Full Text] [Related]
29. Extending the use of stiripentol to other epileptic syndromes: a case of PCDH19-related epilepsy. Trivisano M; Specchio N; Vigevano F Eur J Paediatr Neurol; 2015 Mar; 19(2):248-50. PubMed ID: 25510386 [TBL] [Abstract][Full Text] [Related]
30. The pharmacologic treatment of Dravet syndrome. Chiron C; Dulac O Epilepsia; 2011 Apr; 52 Suppl 2():72-5. PubMed ID: 21463285 [TBL] [Abstract][Full Text] [Related]
31. Switching from zonisamide to perampanel improved the frequency of seizures caused by hyperthermia in Dravet syndrome: a case report. Horiuchi K; Kudo A; Nakamura S; Yamada K; Inoue T; Fujii S; Oshima Y J Med Case Rep; 2024 Jan; 18(1):3. PubMed ID: 38167335 [TBL] [Abstract][Full Text] [Related]
32. A critical evaluation of fenfluramine hydrochloride for the treatment of Dravet syndrome. Schoonjans AS; Ceulemans B Expert Rev Neurother; 2022 May; 22(5):351-364. PubMed ID: 33455486 [TBL] [Abstract][Full Text] [Related]
33. Stiripentol: A Novel Antiseizure Medication for the Management of Dravet Syndrome. Buck ML; Goodkin HP Ann Pharmacother; 2019 Nov; 53(11):1136-1144. PubMed ID: 31167540 [No Abstract] [Full Text] [Related]
34. Low-dose fenfluramine significantly reduces seizure frequency in Dravet syndrome: a prospective study of a new cohort of patients. Schoonjans A; Paelinck BP; Marchau F; Gunning B; Gammaitoni A; Galer BS; Lagae L; Ceulemans B Eur J Neurol; 2017 Feb; 24(2):309-314. PubMed ID: 27790834 [TBL] [Abstract][Full Text] [Related]
35. Targeted Molecular Strategies for Genetic Neurodevelopmental Disorders: Emerging Lessons from Dravet Syndrome. Lersch R; Jannadi R; Grosse L; Wagner M; Schneider MF; von Stülpnagel C; Heinen F; Potschka H; Borggraefe I Neuroscientist; 2023 Dec; 29(6):732-750. PubMed ID: 35414300 [TBL] [Abstract][Full Text] [Related]
36. Development of an antiseizure drug screening platform for Dravet syndrome at the NINDS contract site for the Epilepsy Therapy Screening Program. Pernici CD; Mensah JA; Dahle EJ; Johnson KJ; Handy L; Buxton L; Smith MD; West PJ; Metcalf CS; Wilcox KS Epilepsia; 2021 Jul; 62(7):1665-1676. PubMed ID: 34002394 [TBL] [Abstract][Full Text] [Related]
37. Fenfluramine increases survival and reduces markers of neurodegeneration in a mouse model of Dravet syndrome. Cha J; Filatov G; Smith SJ; Gammaitoni AR; Lothe A; Reeder T Epilepsia Open; 2024 Feb; 9(1):300-313. PubMed ID: 38018342 [TBL] [Abstract][Full Text] [Related]
38. Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results. Laux LC; Bebin EM; Checketts D; Chez M; Flamini R; Marsh ED; Miller I; Nichol K; Park Y; Segal E; Seltzer L; Szaflarski JP; Thiele EA; Weinstock A; Epilepsy Res; 2019 Aug; 154():13-20. PubMed ID: 31022635 [TBL] [Abstract][Full Text] [Related]
39. A Practical Guide to the Treatment of Dravet Syndrome with Anti-Seizure Medication. Strzelczyk A; Schubert-Bast S CNS Drugs; 2022 Mar; 36(3):217-237. PubMed ID: 35156171 [TBL] [Abstract][Full Text] [Related]
40. Efficacy of Stiripentol and the Clinical Outcome in Dravet Syndrome. Yıldız EP; Ozkan MU; Uzunhan TA; Bektaş G; Tatlı B; Aydınlı N; Çalışkan M; Özmen M J Child Neurol; 2019 Jan; 34(1):33-37. PubMed ID: 30362398 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]